Merck investing even more in its cancer portfolio – a growing trend among the top pharma companies.
Takeda seeking to grow its Amitiza franchise, now that Novartis’ Zelnorm has been pulled from the market.
Novartis gets approval for patch version of its Alzheimer’s drug Exelon.
More encouragement on the anti-blood-clotting front – BMS/Pfizer experimental drug apixaban meets goals in a mid-stage study. And, Bayer’s experimental rivaroxaban is more effective than standard injections of Lovenox in preventing blood clots after knee surgery.
Can Pfizer’s anti-smoking drug also be effective to help curb drinking?
GE and Abbott agree to disagree on the acquisition of Abbott’s diagnostics biz – the deal’s off.